We deliver end-to-end services from protein sequence through protein expression, purification, crystallization, structural determination, to advanced X-ray based compound screening and innovative de novo protein design for cutting-edge drug discovery. Our automated pipeline serves the diverse needs of pharmaceutical companies, biotechnology firms and academic laboratories engaged in drug development, biological research, and protein engineering.
Gene to protein
GIOS offers a comprehensive gene-to-protein service, providing researchers and biotechnology companies with high-quality, purified proteins. Customers simply provide a protein or gene sequence, and we take care of the entire process, from expression to purification, delivering the final protein product in a ready-to-use form. Our current expertise lies in E. coli-based expression systems, ensuring efficient and scalable production. Additionally, we are actively expanding our capabilities to include other expression platforms, enabling even broader applications and customization options to meet diverse research and development needs.
Protein to structure
GIOS Biostructures specializes in X-ray crystallography, providing high-resolution structural insights to support drug discovery and biotechnology research. With access to modern high-brightness X-ray sources equipped with advanced detectors, we ensure the collection of high-quality diffraction data, leading to accurate structural models. Our expertise extends beyond conventional proteins, encompassing engineered and computationally designed proteins, including those developed through de novo protein design. By integrating advanced methodologies, we enable precise structural characterization of both natural and synthetic biomolecules, supporting structure-based drug discovery and rational protein engineering.
Fragment-based screening
X-ray-based fragment screening has emerged as the most sensitive and effective method for identifying druggable sites. GIOS Biostructures aims to enable access to this technology by offering small-scale fragment screens, providing a cost-effective approach to assess the druggability of target proteins. Our screening platform is designed to uncover druggable sites, including cryptic pockets, which are often overlooked by conventional methods.
AI-based protein design
Protein design
De novo protein design is an emerging and rapidly evolving field that enables the creation of entirely new protein structures tailored for specific functions. At GIOS Biostructures, we leverage cutting-edge computational methods to design proteins based on a given target, scaffold, or sequence. With access to advanced GPU computing infrastructure, we can generate and refine complex protein architectures, including large and intricate designs that were previously unattainable. Utilizing state-of-the-art sequence generation neural networks, our approach allows for precise control over structural and functional properties.
Protein engineering
In addition to de novo design, we specialize in protein engineering to enhance the solubility and stability of demanding targets. Our proprietary GIOS MESO platform™ is specifically developed to transform insoluble proteins, including membrane proteins, into soluble, well-expressed variants suitable for downstream applications. These optimized designs seamlessly integrate into our protein-to-structure service, ensuring that even the most complex proteins can be successfully expressed, purified, and structurally characterized using X-ray crystallography and other biophysical methods.